Drug Type Trispecific T-cell engager (TriTE) |
Synonyms- |
Target |
Mechanism CD28 agonists(T-cell-specific surface glycoprotein CD28 agonists), CD3 stimulants(T cell surface glycoprotein CD3 stimulants), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Preclinical | US | 23 Feb 2022 |